Amplia Therapeutics Limited (Amplia or the Company) announced it has appointed Dr. Mark Devlin as Chief Scientific Officer. Mark will formally commence this role on 31 August 2020. As Biology Leader of the Cooperative Research Centre (CRC) for Cancer Therapeutics, Mark was directly involved with the programs that resulted in the initial discovery and development of Amplia's proprietary Focal Adhesion Kinase (FAK) inhibitor drugs AMP945 and AMP886. He has continued to play an important and active role as a scientific advisor to the company since it was established as a publicly listed company via its acquisition by Innate Therapeutics in May 2018. Most recently, Mark was Chief Executive Officer of CTxONE, a commercial development partner of the CRC for Cancer Therapeutics.